Targeted drug delivery aims to deliver a pharmaceutical compound in a precise, controlled manner directly to the desired organ, tissue, or cells to maximize desired therapeutic outcome and minimize undesired effects. It involves developing biocompatible vehicles to transport therapeutic agents in a targeted way to the appropriate site of action.

The global targeted drug delivery market is estimated to be valued at US$ 761.95 Mn in 2023 and is expected to exhibit a CAGR of 9.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Increased focus on precision medicine is expected to drive the growth of the global targeted drug delivery market. Precision medicine aims to deliver personalized medical care through a targeted approach by catering to people's variability in genes, environment, and lifestyle. Targeted drug delivery allows for the treatment of diseases through precision medicine by directing the drug only to the targeted site, thereby avoiding side effects and maximizing therapeutic benefits. This is expected to fuel the adoption of targeted drug delivery techniques. Increased R&D investments and initiatives by leading pharmaceutical companies as well as governments of various countries to develop more advanced and effective targeted drug delivery systems is also propelling the market growth.

SWOT Analysis

Strength: Targeted drug delivery offers several advantages over traditional drug delivery methods. It allows for targeted treatment of diseased cells and tissues while reducing potential side effects on healthy cells. This helps improve efficacy and safety profiles of drugs. It also enables delivery of drugs that would otherwise not be able to reach their target site due to various biological, physiological and pharmacological barriers in the body.

Weakness: Developing targeted drug delivery systems is technically challenging and requires multidisciplinary expertise. These complex systems need to protect the drug payload until it reaches the desired site while also ensuring efficient release of drugs at the targeted location. This lengthy and expensive research and development process means that targeted therapies often have high costs.

Opportunity: The growing target patient population for conditions like cancer, cardiovascular diseases, neurological disorders etc. offers significant market potential for targeted drug delivery. Increasing investment in R&D by pharmaceutical companies to develop advanced drug delivery technologies also present opportunities. Furthermore, the rising demand for personalized medicines with higher efficacy, safety and patient compliance presents an opportunity to leverage targeted drug delivery approaches.

Threats: Manufacturing processes for targeted drug delivery systems need to meet stringent quality requirements. Drug delivery technologies are also dependent on advances in fields like nanotechnology and biotechnology. Issues in sourcing raw materials, scaling up production according to cGMP standards and gaining regulatory approvals pose threats. Biosimilars emerging as lower cost alternatives can impact the adoption of novel targeted therapies.

Key Takeaways

The Global Targeted Drug Delivery Market Size is expected to witness high growth. It is forecast to register a CAGR of 9.5% during the forecast period of 2023 to 2030. The market size is projected to reach US$761.95 Mn in 2023.

North America dominates the global targeted drug delivery market currently owing to growing clinical research, favorable reimbursement policies and increasing adoption of advanced therapies. Asia Pacific is expected to be the fastest growing regional market during the forecast period driven by rising healthcare investments, expanding patient pool and improving regulatory standards in countries like China and India.

Key players operating in the targeted drug delivery market are AbbVie Inc., Ablynx NV by Sanofi SA, Arrowhead Pharmaceuticals, Inc., Baxter International Inc., AstraZeneca PLC, Boston Scientific Corporation, Becton, Depomed, Inc., Fraunhofer Gesellschaft Munchen, Janssen Global Services, LLC., Luye Pharma Group, Pfizer Inc., Quark Pharmaceuticals Inc., Rexahn Pharmaceuticals Inc., Savara Inc., Roche Holding AG, Suda Limited, Vectura Group PLC, Taiwan Liposome Company, Ltd., and 3M Company.

For more insights, read- https://www.zupyak.com/p/3960070/t/the-global-targeted-drug-delivery-market-growth-accelerated-by-need-for-effective-drug-administration